Skip to main content

Table 4 Incidence of adverse events with vortioxetine in the Chinese population across the three studies

From: Pharmacokinetics and Safety of Vortioxetine in the Chinese Population

Adverse events by preferred term Study 1 Study 2 Study 3
Single-dose (overall), n (%) (n = 16) Single dose, n (%) (n = 32) Multiple dose, n (%) (n = 32) Vortioxetine group
Core treatment period (n = 124)
10 mg (n = 16) 20 mg (n = 16) 10 mg (n = 16) 20 mg (n = 16)
Nausea 1 (6) 4 (25) 6 (37.5) 25 (20.2)
Dizziness 1 (6) 1 (6.3) 12 (9.7)
Dry mouth 7 (5.6)
Decreased appetite 2 (12.5) 5 (4)
Diarrhea 1 (6.3) 4 (3.2)
Fatigue 3 (2.4)
Abdominal distension 1 (6.3) 1 (0.8)
Pruritus 5 (31.3) 13 (81.3) 1 (0.8)
Insomnia 1 (0.8)
Transaminases increased 1 (6.3)
Upper respiratory tract infection 1 (6.3)
White blood cell count increased 1 (6.3)